About this trial
This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia
Patient Profile
Patients with Relapsed/Refractory Acute Myeloid Leukaemia
Where’s this trial being run?
University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | BCNI GMI-1271-301 |
|---|---|
| Number: | 21-08 |
| Full Title: | A Phase III Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia |
| Principal Investigator: | Dr Janusz Krawczyk (University Hospital Galway) |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | GlycoMimetics Incorporated |
| Recruitment Started: |
Global: 15-Oct-2018 Ireland: 15-Aug-2019 |
| Global Recruitment Target: | 380 |
|---|---|
| Ireland Recruitment Target: | 6 |